Overview

Effect of Rosiglitazone on ADMA in Critical Illness

Status:
Unknown status
Trial end date:
2007-12-01
Target enrollment:
0
Participant gender:
All
Summary
The purpose of this study is to determine whether Rosiglitazone,decreases the ADMA concentration and thereby increases the arginine/ADMA ratio of critically ill patients.
Phase:
Phase 3
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
VU University Medical Center
Treatments:
Rosiglitazone
Criteria
Inclusion Criteria:

- critically ill patients

- age between 18 and 75 years

- SOFA score > 7

Exclusion Criteria:

- history of Diabetes mellitus

- history of hypercholesterolemia

- history of hyperhomocysteinemia

- impaired hepatic function